Market Size of Oculoplastic Surgery Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Oculoplastic Surgery Market Analysis
The oculoplastic surgery market is expected to register a CAGR of 5.5% during the forecast period.
Surgery markets across the world have been negatively impacted due to the disruptions experienced by their respective manufacturing and supply-chain operations as a result of precautionary lockdowns and other restrictions enforced by governing authorities across the globe. Moreover, consumer demand has also subsequently reduced as individuals are now more keen on eliminating non-essential expenses from their respective budgets as the general economic status of most people has been severely affected by the pandemic. The aforementioned factors are expected to burden the revenue trajectory of the global oculoplastic surgery market during the forecast period. This may be attributed to the increasing number of eye-related disorders, age-related oculoplastic surgeries, and technological advancements. For instance, in August 2021, as per the National Library of Medicine, contributors to the burden of eye disease at the global level are refractive errors (27.7 million DALYs), cataracts (17.7 million DALYs), macular degeneration (9.3 million DALYs), glaucoma (4.7 million DALYs), trachoma (1.3 million DALYs), etc. Thus, the increasing number of eye-related disorders is driving the growth of the market studied.
With the growing aging population, there would be an increase in disorders related to the face and eyelids, resulting in the market's growth. For instance, according to the World Health Organization, by 2030, one in six people in the world will be aged 60 years and above. At this time, the share of the population aged 60 years and above will increase from 1 billion in 2020 to 1.4 billion.
Key players operating in the market are focusing on submitting applications for the approval of intraocular lenses, oculoplastic surgery devices, etc., for use in ocular surgery, which is expected to drive the growth of the global oculoplastic surgery market over the forecast period. For instance, in April 2021, Bausch & Lomb Incorporated, a US-based eye health products company, received the United States Food and Drug Administration (FDA) approval for ClearVisc, a dispersive ophthalmic viscosurgical device (OVD) to be used in ocular surgery. ClearVisc contains sorbitol which protects from free radicals during cataract surgery. Moreover, in February 2021, Johnson & Johnson Vision announced that it received the United States Food and Drug Administration (FDA) approval for its TECNIS Eyhance Toric II monofocal intraocular lens (IOL) that can be used in cataract surgery of patients with or without astigmatism, an imperfection in the curvature of the eye.
However, the high cost of surgeries and lack of reimbursement policies may hamper the growth of the market to a certain extent.
